Posted by Michael Wonder on 24 Jan 2018
Proposal to list eplerenone for the treatment of heart failure in patients intolerant to spironolactone
24 January 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to fund eplerenone for the treatment of heart failure in patients intolerant to spironolactone.
A decision has not been made on a preferred tender bid so the brand names, pricing and timing for these changes, if they were to be implemented, is still to be determined.
PHARMAC is seeking feedback on the proposed new investment and funding criteria.
